antigen receptor restriction-compatible with an intense stimulation by a microbial superantigen-in patients with rheumatoid arthritis. In addition, the demonstration of increased susceptibility to the development of rheumatoid arthritis in patients with selected genetic variants of the 1B chain of the T cell receptor' also makes exploration of immune responses to S aureus superantigens in rheumatoid arthritis of significant interest.
S aureus secretes up to 30 different protein antigens, including at least eight T cell superantigens': toxic shock syndrome toxin-l (TSST-1) and staphylococcal enterotoxins A, B, C1, C2, C3, D, and E. This makes S aureus one of the principal sources of currently identified T cell superantigens in the environment. T cell superantigens have a dual affinity for major histocompatibility complex (MHC) class II molecules and for a relatively invariant region of the variable portion of the chain (VD) of the T cell antigen receptor to induce T cell activation in a V[ restricted manner.' Recent studies by Paliard et al 2have shown such T cell antigen receptor restriction-compatible with an intense stimulation by a microbial superantigen-in patients with rheumatoid arthritis. In addition, the demonstration of increased susceptibility to the development of rheumatoid arthritis in patients with selected genetic variants of the 1B chain of the T cell receptor' also makes exploration of immune responses to S aureus superantigens in rheumatoid arthritis of significant interest.
TSST-1 and staphylococcal enterotoxin A (SEA), which are commonly secreted S aureus T cell superantigens, can also act as conventional antigens and elicit antibodies which may protect individuals from their toxic effects. Approximately 91% of healthy subjects have significant antibody titres to TSST-1, and 46% have significant antibody titres to SEA,4 even though only 38% of S aureus strains can produce TSST-1 and about 23% are potential producers of SEA. 45 In addition to TSST-1, SEA, and the other T cell superantigens, S aureus also produces protein A, which is a known B cell superantigen. 6 Protein A stimulates utilisation of the VH3 heavy chain gene6 and induces IgM RF production.7. Like TSST-1 and SEA, protein A can also act as a conventional antigen and has also been shown to induce an antibody response in 31% of rheumatoid arthritis patients.
Rheumatoid arthritis is an inflammatory arthritis of unknown aetiology, and many different infectious agents have been suggested as being involved in the pathogenesis of the disease. S aureus is an attractive candidate because 33% of the normal population are nasal carriers of this ubiquitous organism910 and S aureus secretes both T cell and B cell superantigens. To evaluate S aureus as a possible causative agent in the pathogenesis of rheumatoid arthritis, we compared the antibody titres in rheumatoid arthritis patients and in normal spouses living in the same household to two commonly secreted S aureus superantigens (TSST-1 and SEA) and to crude extracts of two common fecal flora, Escherichia coli and Bacteroides fragilis. We show that rheumatoid arthritis patients have an exaggerated antibody response to TSST-1, but share with spouse controls a similar antibody response to SEA and to the antigens of two other micro-organisms to which they are uniformly exposed.
Methods

PATI1NTS AND CONTROL SUBJECTS
All the rheumatoid arthritis patients included in this study fulfilled the American College of Rheumatology criteria for the diagnosis of rheumatoid arthritis" and were seen as outpa- and 4 than the S aureus isolates from the control subjects (fig 1) . (table 2) . Some of the rheumatoid arthritis patients did show very low responses to the B fragilis antigens when compared to spouse controls or pooled normal human sera, even though they had shown high responses to TSST-1. In both tables 1 and 2, the mean absorbance value of the pool of 500 normal sera was similar to the mean absorbance value of the spouse controls, showing that the average immune response in the sera of the Discussion S aureus may be cultured from asymptomatic normal subjects, not only from the nose (33%), but also from the vagina (4.6%),'" '5 perineum (22%),'6 and skin (12-20%) .9 The 33% nasal carriage rate of the 1 10 control subjects in this study corresponded well with previous studies.9 10 Since nasal S aureus carriers may show persistent or transient positivity, the 33% carriage rate reflects the carrier status of the normal population at the time the nasal cultures were obtained. Transient positivity of nasal carriage and the possibility of carrying S aureus undetected at other loci may help to explain why 91% of healthy subjects have significant antibody titres to TSST-1,5 even though only a third have detectable S aureus in the anterior nares at any given time.91O
A previous study of nasal carriage of S aureus in non-rheumatoid arthritis patients'0 showed an enrichment for patients who were HIA-DR3. Another study'7 suggested that nasal carriage of S aureus depends on the presence of a preferential binding site for the organism on the nasal epithelium, but that study did not show the site to be genetically determined. When 47 selected patients with toxic shock syndrome were studied they showed no identifiable HLA-A, B, C, or DR differences when compared to the known gene frequencies in a racially matched population."
It is not known why rheumatoid arthritis patients have an increased nasal carriage rate of S aureus, but our work confirms an unpublished 1972 study in which 50% of 48 rheumatoid arthritis patients and 27% of 48 controls (matched for age, sex, and race) carried S aureus in their upper nasal vestibule (A McKusick, personal communication). In McKusick's study, which was completed before immunotherapy was used in the treatment of rheumatoid arthritis, no obvious differences in disease severity or type of treatment were associated with the carriage of S aureus in the rheumatoid arthritis patients. Therefore, this 1972 study suggests that the treatment of rheumatoid arthritis patients with immunosuppressive drugs does not increase colonisation of the rheumatoid arthritis patients with S aureus.
DNA fingerprinting"9 or bacteriophage typing'2 may be used to distinguish different strains of S aureus. We used bacteriophage typing to examine the heterogeneity of S aureus strains isolated in this study.'2 Among the 62 S aureus isolates (37 rheumatoid arthritis and 25 normal isolates) that were studied by this method, at least 49 different strains were identified and nine strains were non-typable. The variability and complexity of the lysis profiles and the number of unique strains that were identified suggest that a potentially large number of different S aureus strains exist. One interesting finding of the bacteriophage typing was the prevalence of lysis by group 2 and group 4 bacteriophages among the S aureus strains isolated from rheumatoid arthritis patients (fig 1) . Another interesting finding was that approximately 50% of the isolates obtained from both the rheumatoid arthritis patients and the normal controls were lysed by group 1 bacteriophages. Since group 1 bacteriophages have been associated with a higher frequency ofTSST-1 production, the data suggest that both rheumatoid arthritis and normal controls were exposed to strains secreting TSST-1.
Superantigens have been implicated in the clonal expansion of selected T lymphocytes in toxic shock syndrome,20 rheumatoid arthritis,2 and Kawasaki disease.2' Since S aureus represents one of the main sources of currently known superantigen exposure for humans, we compared the serological response of rheumatoid arthritis patients and their spouses to two common S aureus superantigens, TSST-1 and SEA, with the response to two non-S aureus antigen mixtures from Bfragilis and E coli. Figure 2 and table 1 show the substantial differences in the IgG and IgA antibody responses to TSST-1 between a group ofthe 25 rheumatoid arthritis patients and 11 of their spouses (controls for environmental factors that could influence both exposure to and colonisation of S aureus in the matched rheumatoid arthritis patient). Some subjects in each group were nasal S aureus carriers and some were not carriers. The demonstration of an average of 7.7-fold greater IgG anti-TSST-1 level in rheumatoid arthritis patients who were S aureus carriers compared to the level in the spouse controls who also carried S aureus is impressive (table 3) , and suggests at least four possible explanations: (1) a much more intense immune response to TSST-1 in rheumatoid arthritis than non-rheumatoid arthritis subjects; (2) a much greater average antigen exposure in rheumatoid arthritis due to increased carriage rate; (3) S aureus strain differences in rheumatoid arthritis compared to nonrheumatoid arthritis carriers resulting in either a greater synthesis rate of TSST-1 or variations in the amount of TSST-1 released into the nasal mucosa 15; or (4) Our study also showed that normal control subjects, whether S aureus carriers or not, have similar levels of both IgG and IgA anti-TSST-1 antibodies (table 3) . This latter result is surprising but consistent with earlier studies in toxic shock syndrome in which healthy persons who were vaginal S aureus carriers were compared to other healthy controls not carrying S aureus, and found to have similar levels of anti-TSST-1 antibody. '4 The selective enhancement of the IgG and IgA antibody response to TSST-1 in rheumatoid arthritis patients was not matched by their response to SEA ( 
